"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","characteristics_ch1.5","characteristics_ch1.6","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","platform_id","contact_name","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count"
"GSM526419","Prostate tumor PCA0001 miRNA","GSM526419","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0001","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2A","pathological_stage: T3C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526419/GSM526419.txt.gz","373"
"GSM526420","Prostate tumor PCA0003 miRNA","GSM526420","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0003","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2B","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526420/GSM526420.txt.gz","373"
"GSM526421","Prostate tumor PCA0005 miRNA","GSM526421","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0005","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526421/GSM526421.txt.gz","373"
"GSM526422","Prostate tumor PCA0007 miRNA","GSM526422","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0007","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526422/GSM526422.txt.gz","373"
"GSM526423","Prostate tumor PCA0009 miRNA","GSM526423","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0009","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2A","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526423/GSM526423.txt.gz","373"
"GSM526424","Prostate tumor PCA0012 miRNA","GSM526424","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0012","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526424/GSM526424.txt.gz","373"
"GSM526425","Prostate tumor PCA0017 miRNA","GSM526425","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0017","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2A","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526425/GSM526425.txt.gz","373"
"GSM526426","Prostate tumor PCA0023 miRNA","GSM526426","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0023","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526426/GSM526426.txt.gz","373"
"GSM526427","Prostate tumor PCA0024 miRNA","GSM526427","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0024","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526427/GSM526427.txt.gz","373"
"GSM526428","Prostate tumor PCA0027 miRNA","GSM526428","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0027","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 5","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526428/GSM526428.txt.gz","373"
"GSM526429","Prostate tumor PCA0029 miRNA","GSM526429","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0029","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2B","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526429/GSM526429.txt.gz","373"
"GSM526430","Prostate tumor PCA0033 miRNA","GSM526430","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0033","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2B","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526430/GSM526430.txt.gz","373"
"GSM526431","Prostate tumor PCA0040 miRNA","GSM526431","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0040","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2A","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526431/GSM526431.txt.gz","373"
"GSM526432","Prostate tumor PCA0050 miRNA","GSM526432","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0050","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2B","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526432/GSM526432.txt.gz","373"
"GSM526433","Prostate tumor PCA0054 miRNA","GSM526433","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0054","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T3C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526433/GSM526433.txt.gz","373"
"GSM526434","Prostate tumor PCA0056 miRNA","GSM526434","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0056","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526434/GSM526434.txt.gz","373"
"GSM526435","Prostate tumor PCA0057 miRNA","GSM526435","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0057","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526435/GSM526435.txt.gz","373"
"GSM526436","Prostate tumor PCA0062 miRNA","GSM526436","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0062","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526436/GSM526436.txt.gz","373"
"GSM526437","Prostate tumor PCA0063 miRNA","GSM526437","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0063","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2B","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526437/GSM526437.txt.gz","373"
"GSM526438","Prostate tumor PCA0064 miRNA","GSM526438","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0064","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2B","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526438/GSM526438.txt.gz","373"
"GSM526439","Prostate tumor PCA0065 miRNA","GSM526439","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0065","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526439/GSM526439.txt.gz","373"
"GSM526440","Prostate tumor PCA0066 miRNA","GSM526440","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0066","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2B","pathological_stage: T3B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526440/GSM526440.txt.gz","373"
"GSM526441","Prostate tumor PCA0074 miRNA","GSM526441","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0074","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526441/GSM526441.txt.gz","373"
"GSM526442","Prostate tumor PCA0075 miRNA","GSM526442","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0075","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2A","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526442/GSM526442.txt.gz","373"
"GSM526443","Prostate tumor PCA0077 miRNA","GSM526443","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0077","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2B","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526443/GSM526443.txt.gz","373"
"GSM526444","Prostate tumor PCA0080 miRNA","GSM526444","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0080","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 8","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526444/GSM526444.txt.gz","373"
"GSM526445","Prostate tumor PCA0081 miRNA","GSM526445","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0081","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2B","pathological_stage: T4","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526445/GSM526445.txt.gz","373"
"GSM526446","Prostate tumor PCA0082 miRNA","GSM526446","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0082","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526446/GSM526446.txt.gz","373"
"GSM526447","Prostate tumor PCA0086 miRNA","GSM526447","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0086","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T2A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526447/GSM526447.txt.gz","373"
"GSM526448","Prostate tumor PCA0087 miRNA","GSM526448","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0087","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2C","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526448/GSM526448.txt.gz","373"
"GSM526449","Prostate tumor PCA0089 miRNA","GSM526449","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0089","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526449/GSM526449.txt.gz","373"
"GSM526450","Prostate tumor PCA0090 miRNA","GSM526450","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0090","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T3B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526450/GSM526450.txt.gz","373"
"GSM526451","Prostate tumor PCA0092 miRNA","GSM526451","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0092","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T3A","pathological_stage: T4","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526451/GSM526451.txt.gz","373"
"GSM526452","Prostate tumor PCA0093 miRNA","GSM526452","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0093","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526452/GSM526452.txt.gz","373"
"GSM526453","Prostate tumor PCA0094 miRNA","GSM526453","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0094","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526453/GSM526453.txt.gz","373"
"GSM526454","Prostate tumor PCA0095 miRNA","GSM526454","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0095","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T4","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526454/GSM526454.txt.gz","373"
"GSM526455","Prostate tumor PCA0096 miRNA","GSM526455","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0096","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2A","pathological_stage: T3B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526455/GSM526455.txt.gz","373"
"GSM526456","Prostate tumor PCA0097 miRNA","GSM526456","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0097","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526456/GSM526456.txt.gz","373"
"GSM526457","Prostate tumor PCA0099 miRNA","GSM526457","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0099","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 9","clint_stage: T2C","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526457/GSM526457.txt.gz","373"
"GSM526458","Prostate tumor PCA0101 miRNA","GSM526458","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0101","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526458/GSM526458.txt.gz","373"
"GSM526459","Prostate tumor PCA0103 miRNA","GSM526459","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0103","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526459/GSM526459.txt.gz","373"
"GSM526460","Prostate tumor PCA0104 miRNA","GSM526460","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0104","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2A","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526460/GSM526460.txt.gz","373"
"GSM526461","Prostate tumor PCA0105 miRNA","GSM526461","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0105","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526461/GSM526461.txt.gz","373"
"GSM526462","Prostate tumor PCA0107 miRNA","GSM526462","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0107","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2B","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526462/GSM526462.txt.gz","373"
"GSM526463","Prostate tumor PCA0108 miRNA","GSM526463","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0108","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T3A","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526463/GSM526463.txt.gz","373"
"GSM526464","Prostate tumor PCA0109 miRNA","GSM526464","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0109","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526464/GSM526464.txt.gz","373"
"GSM526465","Prostate tumor PCA0110 miRNA","GSM526465","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0110","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526465/GSM526465.txt.gz","373"
"GSM526466","Prostate tumor PCA0111 miRNA","GSM526466","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0111","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526466/GSM526466.txt.gz","373"
"GSM526467","Prostate tumor PCA0112 miRNA","GSM526467","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0112","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 8","clint_stage: T3A","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526467/GSM526467.txt.gz","373"
"GSM526468","Prostate tumor PCA0113 miRNA","GSM526468","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0113","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526468/GSM526468.txt.gz","373"
"GSM526469","Prostate tumor PCA0114 miRNA","GSM526469","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0114","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526469/GSM526469.txt.gz","373"
"GSM526470","Prostate tumor PCA0115 miRNA","GSM526470","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0115","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2A","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526470/GSM526470.txt.gz","373"
"GSM526471","Prostate tumor PCA0117 miRNA","GSM526471","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0117","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 8","clint_stage: T1C","pathological_stage: T3B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526471/GSM526471.txt.gz","373"
"GSM526472","Prostate tumor PCA0118 miRNA","GSM526472","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0118","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526472/GSM526472.txt.gz","373"
"GSM526473","Prostate tumor PCA0119 miRNA","GSM526473","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0119","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526473/GSM526473.txt.gz","373"
"GSM526474","Prostate tumor PCA0120 miRNA","GSM526474","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0120","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526474/GSM526474.txt.gz","373"
"GSM526475","Prostate tumor PCA0122 miRNA","GSM526475","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0122","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526475/GSM526475.txt.gz","373"
"GSM526476","Prostate tumor PCA0124 miRNA","GSM526476","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0124","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2A","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526476/GSM526476.txt.gz","373"
"GSM526477","Prostate tumor PCA0125 miRNA","GSM526477","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0125","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2C","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526477/GSM526477.txt.gz","373"
"GSM526478","Prostate tumor PCA0126 miRNA","GSM526478","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0126","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526478/GSM526478.txt.gz","373"
"GSM526479","Prostate tumor PCA0127 miRNA","GSM526479","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0127","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 8","clint_stage: T2A","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526479/GSM526479.txt.gz","373"
"GSM526480","Prostate tumor PCA0128 miRNA","GSM526480","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0128","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2A","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526480/GSM526480.txt.gz","373"
"GSM526481","Prostate tumor PCA0129 miRNA","GSM526481","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0129","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2A","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526481/GSM526481.txt.gz","373"
"GSM526482","Prostate tumor PCA0130 miRNA","GSM526482","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0130","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 8","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526482/GSM526482.txt.gz","373"
"GSM526483","Prostate tumor PCA0132 miRNA","GSM526483","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0132","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2A","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526483/GSM526483.txt.gz","373"
"GSM526484","Prostate tumor PCA0134 miRNA","GSM526484","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0134","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2A","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526484/GSM526484.txt.gz","373"
"GSM526485","Prostate tumor PCA0135 miRNA","GSM526485","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0135","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526485/GSM526485.txt.gz","373"
"GSM526486","Prostate tumor PCA0136 miRNA","GSM526486","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0136","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526486/GSM526486.txt.gz","373"
"GSM526487","Prostate tumor PCA0141 miRNA","GSM526487","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0141","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526487/GSM526487.txt.gz","373"
"GSM526488","Prostate tumor PCA0144 miRNA","GSM526488","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0144","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526488/GSM526488.txt.gz","373"
"GSM526489","Prostate tumor PCA0145 miRNA","GSM526489","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0145","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526489/GSM526489.txt.gz","373"
"GSM526490","Prostate tumor PCA0146 miRNA","GSM526490","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0146","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526490/GSM526490.txt.gz","373"
"GSM526491","Prostate tumor PCA0147 miRNA","GSM526491","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0147","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526491/GSM526491.txt.gz","373"
"GSM526492","Prostate tumor PCA0149 miRNA","GSM526492","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0149","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2C","pathological_stage: T3B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526492/GSM526492.txt.gz","373"
"GSM526493","Prostate tumor PCA0151 miRNA","GSM526493","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0151","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526493/GSM526493.txt.gz","373"
"GSM526494","Prostate tumor PCA0155 miRNA","GSM526494","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0155","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2A","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526494/GSM526494.txt.gz","373"
"GSM526495","Prostate tumor PCA0156 miRNA","GSM526495","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0156","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T4","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526495/GSM526495.txt.gz","373"
"GSM526496","Prostate tumor PCA0157 miRNA","GSM526496","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0157","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526496/GSM526496.txt.gz","373"
"GSM526497","Prostate tumor PCA0158 miRNA","GSM526497","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0158","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526497/GSM526497.txt.gz","373"
"GSM526498","Prostate tumor PCA0159 miRNA","GSM526498","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0159","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2A","pathological_stage: T3B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526498/GSM526498.txt.gz","373"
"GSM526499","Prostate tumor PCA0160 miRNA","GSM526499","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0160","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526499/GSM526499.txt.gz","373"
"GSM526500","Prostate tumor PCA0161 miRNA","GSM526500","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0161","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526500/GSM526500.txt.gz","373"
"GSM526501","Prostate tumor PCA0162 miRNA","GSM526501","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0162","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526501/GSM526501.txt.gz","373"
"GSM526502","Prostate tumor PCA0163 miRNA","GSM526502","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0163","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526502/GSM526502.txt.gz","373"
"GSM526503","Prostate tumor PCA0164 miRNA","GSM526503","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0164","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526503/GSM526503.txt.gz","373"
"GSM526504","Prostate tumor PCA0165 miRNA","GSM526504","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0165","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526504/GSM526504.txt.gz","373"
"GSM526505","Prostate tumor PCA0167 miRNA","GSM526505","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0167","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2B","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526505/GSM526505.txt.gz","373"
"GSM526506","Prostate tumor PCA0168 miRNA","GSM526506","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0168","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526506/GSM526506.txt.gz","373"
"GSM526507","Prostate tumor PCA0169 miRNA","GSM526507","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0169","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526507/GSM526507.txt.gz","373"
"GSM526508","Prostate tumor PCA0170 miRNA","GSM526508","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0170","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T2B","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526508/GSM526508.txt.gz","373"
"GSM526509","Prostate tumor PCA0171 miRNA","GSM526509","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0171","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T2A","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526509/GSM526509.txt.gz","373"
"GSM526510","Prostate tumor PCA0172 miRNA","GSM526510","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0172","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 8","clint_stage: T1C","pathological_stage: T4","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526510/GSM526510.txt.gz","373"
"GSM526511","Prostate tumor PCA0173 miRNA","GSM526511","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0173","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T3B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526511/GSM526511.txt.gz","373"
"GSM526512","Prostate tumor PCA0174 miRNA","GSM526512","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0174","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526512/GSM526512.txt.gz","373"
"GSM526513","Prostate tumor PCA0175 miRNA","GSM526513","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0175","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526513/GSM526513.txt.gz","373"
"GSM526514","Prostate tumor PCA0178 miRNA","GSM526514","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0178","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526514/GSM526514.txt.gz","373"
"GSM526515","Prostate tumor PCA0179 miRNA","GSM526515","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0179","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 9","clint_stage: T1C","pathological_stage: T3B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526515/GSM526515.txt.gz","373"
"GSM526516","Prostate tumor PCA0180 miRNA","GSM526516","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0180","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526516/GSM526516.txt.gz","373"
"GSM526517","Prostate tumor PCA0181 miRNA","GSM526517","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0181","tissue: Prostate","disease status: prostate cancer","tumor type: Primary tumor","biopsy_gleason_grade: 9","clint_stage: T1C","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526517/GSM526517.txt.gz","373"
"GSM526518","Prostate tumor PCA0184 miRNA","GSM526518","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0184","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: 6","clint_stage: T1C","pathological_stage: NA","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526518/GSM526518.txt.gz","373"
"GSM526519","Prostate tumor PCA0187 miRNA","GSM526519","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0187","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: 7","clint_stage: T2C","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526519/GSM526519.txt.gz","373"
"GSM526520","Prostate tumor PCA0189 miRNA","GSM526520","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0189","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: 8","clint_stage: T2B","pathological_stage: NA","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526520/GSM526520.txt.gz","373"
"GSM526521","Prostate tumor PCA0190 miRNA","GSM526521","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0190","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: NA","clint_stage: NA","pathological_stage: NA","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526521/GSM526521.txt.gz","373"
"GSM526522","Prostate tumor PCA0194 miRNA","GSM526522","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0194","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: 6","clint_stage: NA","pathological_stage: NA","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526522/GSM526522.txt.gz","373"
"GSM526523","Prostate tumor PCA0199 miRNA","GSM526523","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0199","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: 9","clint_stage: T4","pathological_stage: T4","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526523/GSM526523.txt.gz","373"
"GSM526524","Prostate tumor PCA0200 miRNA","GSM526524","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0200","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: 9","clint_stage: T1C","pathological_stage: T3B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526524/GSM526524.txt.gz","373"
"GSM526525","Prostate tumor PCA0201 miRNA","GSM526525","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0201","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: 7","clint_stage: T2C","pathological_stage: T3B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526525/GSM526525.txt.gz","373"
"GSM526526","Prostate tumor PCA0203 miRNA","GSM526526","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0203","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: 8","clint_stage: T2","pathological_stage: T2B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526526/GSM526526.txt.gz","373"
"GSM526527","Prostate tumor PCA0206 miRNA","GSM526527","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0206","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T4","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526527/GSM526527.txt.gz","373"
"GSM526528","Prostate tumor PCA0207 miRNA","GSM526528","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0207","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T3A","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526528/GSM526528.txt.gz","373"
"GSM526529","Prostate tumor PCA0208 miRNA","GSM526529","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0208","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: 7","clint_stage: T1C","pathological_stage: T3B","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526529/GSM526529.txt.gz","373"
"GSM526530","Prostate tumor PCA0211 miRNA","GSM526530","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0211","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: 9","clint_stage: NA","pathological_stage: NA","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526530/GSM526530.txt.gz","373"
"GSM526531","Prostate tumor PCA0213 miRNA","GSM526531","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate","Homo sapiens","sample id: PCA0213","tissue: Prostate","disease status: prostate cancer","tumor type: Metastasis","biopsy_gleason_grade: 7","clint_stage: NA","pathological_stage: T3C","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526531/GSM526531.txt.gz","373"
"GSM526532","Cell line Vcap miRNA","GSM526532","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human prostate cancer cell line","Homo sapiens","sample id: Vcap","tissue: Prostate","cell type: prostate cancer cell line","cell line: Vcap","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526532/GSM526532.txt.gz","373"
"GSM526533","Prostate normal PAN0151 miRNA","GSM526533","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0151","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526533/GSM526533.txt.gz","373"
"GSM526534","Prostate normal PAN0157 miRNA","GSM526534","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0157","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526534/GSM526534.txt.gz","373"
"GSM526535","Prostate normal PAN0164 miRNA","GSM526535","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0164","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526535/GSM526535.txt.gz","373"
"GSM526536","Prostate normal PAN0113 miRNA","GSM526536","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0113","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526536/GSM526536.txt.gz","373"
"GSM526537","Prostate normal PAN0107 miRNA","GSM526537","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0107","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526537/GSM526537.txt.gz","373"
"GSM526538","Prostate normal PAN0109 miRNA","GSM526538","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0109","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526538/GSM526538.txt.gz","373"
"GSM526539","Prostate normal PAN0110 miRNA","GSM526539","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0110","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526539/GSM526539.txt.gz","373"
"GSM526540","Prostate normal PAN0112 miRNA","GSM526540","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0112","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526540/GSM526540.txt.gz","373"
"GSM526541","Prostate normal PAN0114 miRNA","GSM526541","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0114","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526541/GSM526541.txt.gz","373"
"GSM526542","Prostate normal PAN0115 miRNA","GSM526542","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0115","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526542/GSM526542.txt.gz","373"
"GSM526543","Prostate normal PAN0122 miRNA","GSM526543","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0122","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526543/GSM526543.txt.gz","373"
"GSM526544","Prostate normal PAN0125 miRNA","GSM526544","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0125","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526544/GSM526544.txt.gz","373"
"GSM526545","Prostate normal PAN0117 miRNA","GSM526545","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0117","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526545/GSM526545.txt.gz","373"
"GSM526546","Prostate normal PAN0120 miRNA","GSM526546","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0120","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526546/GSM526546.txt.gz","373"
"GSM526547","Prostate normal PAN0127 miRNA","GSM526547","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0127","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526547/GSM526547.txt.gz","373"
"GSM526548","Prostate normal PAN0128 miRNA","GSM526548","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0128","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526548/GSM526548.txt.gz","373"
"GSM526549","Prostate normal PAN0129 miRNA","GSM526549","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0129","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526549/GSM526549.txt.gz","373"
"GSM526550","Prostate normal PAN0134 miRNA","GSM526550","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0134","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526550/GSM526550.txt.gz","373"
"GSM526551","Prostate normal PAN0135 miRNA","GSM526551","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0135","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526551/GSM526551.txt.gz","373"
"GSM526552","Prostate normal PAN0136 miRNA","GSM526552","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0136","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526552/GSM526552.txt.gz","373"
"GSM526553","Prostate normal PAN0144 miRNA","GSM526553","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0144","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526553/GSM526553.txt.gz","373"
"GSM526554","Prostate normal PAN0147 miRNA","GSM526554","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0147","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526554/GSM526554.txt.gz","373"
"GSM526555","Prostate normal PAN0162 miRNA","GSM526555","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0162","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526555/GSM526555.txt.gz","373"
"GSM526556","Prostate normal PAN0167 miRNA","GSM526556","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0167","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526556/GSM526556.txt.gz","373"
"GSM526557","Prostate normal PAN0169 miRNA","GSM526557","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0169","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526557/GSM526557.txt.gz","373"
"GSM526558","Prostate normal PAN0171 miRNA","GSM526558","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0171","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526558/GSM526558.txt.gz","373"
"GSM526559","Prostate normal PAN0172 miRNA","GSM526559","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0172","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526559/GSM526559.txt.gz","373"
"GSM526560","Prostate normal PAN0174 miRNA","GSM526560","Public on Jun 24 2010","Mar 24 2010","Jun 15 2010","RNA","1","human adjacent normal prostate","Homo sapiens","sample id: PAN0174","tissue: Prostate","disease status: normal adjacent benign prostate","","","","","total RNA","Total RNA was isolaged using TRIzol@Reagent Total RNA Isoloation (Invitrogen), quantified with Thermo Scientific NanoDrop 1000 Spectrophotometer, and quality controlled with RNA 6000 picoAssay and Bioanalyzer 2100 (Agilent).","Cy3","200ng of total RNA was labeled using the miRNA Complete Labeling and Hybridization Kit (Agilent)","9606","Per manufacturer's instructions","Per manufacturer's instructions","microRNA expression profiling","Images were quantified using Agilent Feature Extraction version 9.5 and data was normalized with between-array variance stabilization normalization (VSN) after excluding any microRNA not present in >80% of the samples profiled","GPL8227","Barry,Stephen,Taylor","Memorial Sloan-Kettering Cancer Center","1275 York Avenue, Box #460","New York","NY","10065","USA","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM526nnn/GSM526560/GSM526560.txt.gz","373"
